Allurion Technologies (ALUR) Stock Price, News & Analysis

Company Overview

Allurion Technologies Inc. focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon), as well as offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite. Allurion Technologies Inc. is headquartered in Natick, Massachusetts.

Key Stats

• Today's Range: $2.75 to $2.97
• 50-Day Range: $2.22 to $3.60
• 52-Week Range: $2.15 to $88.75
• Volume: 149,920 shs
• Average Volume: 772,256 shs
• Market Capitalization: $20.70 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $22.83
• Consensus Rating: Buy

Allurion Technologies Stock Analysis - MarketRank™

Allurion Technologies scored higher than 68% of companies evaluated by MarketBeat, and ranked 305th out of 918 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Allurion Technologies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Allurion Technologies has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Allurion Technologies are expected to grow in the coming year, from ($9.96) to ($7.39) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Allurion Technologies is -0.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Allurion Technologies is -0.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.23% of the float of Allurion Technologies has been sold short.

Short Interest Ratio / Days to Cover

Allurion Technologies has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Allurion Technologies has recently decreased by 18.72%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Allurion Technologies does not currently pay a dividend.

Dividend Growth

Allurion Technologies does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.23% of the float of Allurion Technologies has been sold short.

Short Interest Ratio / Days to Cover

Allurion Technologies has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Allurion Technologies has recently decreased by 18.72%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: 0.33

News Sentiment

Allurion Technologies has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.77 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Allurion Technologies this week, compared to 2 articles on an average week.

Search Interest

7 people have searched for ALUR on MarketBeat in the last 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Allurion Technologies insiders have bought more of their company's stock than they have sold. Specifically, they have bought $26,800.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

22.40% of the stock of Allurion Technologies is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 21.39% of the stock of Allurion Technologies is held by institutions.

ALUR Stock Analysis - Frequently Asked Questions

How have ALUR shares performed this year?

Allurion Technologies' stock was trading at $10.75 on January 1st, 2025. Since then, ALUR stock has decreased by 74.2% and is now trading at $2.7760.
View the best growth stocks for 2025 here.

How were Allurion Technologies' earnings last quarter?

Allurion Technologies Inc. (NYSE:ALUR) announced its earnings results on Wednesday, May, 14th. The company reported $0.43 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.53) by $1.96. The company earned $5.58 million during the quarter, compared to analyst estimates of $5.50 million.
Read the conference call transcript.

When did Allurion Technologies' stock split?

Allurion Technologies's stock reverse split before market open on Friday, January 3rd 2025. The 1-25 reverse split was announced on Tuesday, December 24th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, January 2nd 2025. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

Who are Allurion Technologies' major shareholders?

Top institutional investors of Allurion Technologies include Unisphere Establishment (0.67%), XTX Topco Ltd (0.27%) and Simplex Trading LLC.
View institutional ownership trends.

How do I buy shares of Allurion Technologies?

Shares of ALUR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Allurion Technologies own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Allurion Technologies investors own include NVIDIA (NVDA), Meta Platforms (META), Nuvation Bio (NUVB), Taiwan Semiconductor Manufacturing (TSM), Advanced Micro Devices (AMD), Amprius Technologies (AMPX) and Applied Digital (APLD).

Company Calendar

• Last Earnings: 5/14/2025
• Today: 5/25/2025
• Next Earnings (Estimated): 8/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Surgical & medical instruments
• Sub-Industry: Medical Equipment
• Current Symbol: NYSE:ALUR
• Previous Symbol: NYSE:ALUR
• CIK: 1964979
• Web: www.allurion.com
• Phone: 508-647-4000
• Fax: N/A
• Employees: 501
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $22.83
• High Stock Price Target: $50.00
• Low Stock Price Target: $2.50
• Potential Upside/Downside: +722.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 4 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($12.50)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-80,610,000.00
• Net Margins: -71.24%
• Pretax Margin: -70.14%
• Return on Equity: N/A
• Return on Assets: -56.75%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.33
• Quick Ratio: 2.09

Sales & Book Value

• Annual Sales: $28.30 million
• Price / Sales: 0.73
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($36.95) per share
• Price / Book: -0.08

Miscellaneous

• Outstanding Shares: 7,458,000
• Free Float: 2,011,000
• Market Cap: $20.70 million
• Optionable: Optionable
• Beta: -0.58